| Adverse effect |
Odds ratio; 95% CI; heterogeneity; N of studies, N of participants |
P value |
| Blurred vision |
OR 0.19, 95% CI 0.01 to 4.12; 1 study, 142 participants |
P = 0.29 |
| Dizziness |
OR 1.00, 95% CI 0.51 to 1.98; 1 study, 142 participants |
P = 1.00 |
| Drowsiness |
OR 0.34, 95% CI 0.15 to 0.79; 1 study, 142 participants |
P = 0.01 |
| Hair loss |
OR 1.00, 95% CI 0.14 to 7.30; 1 study, 142 participants |
P = 1.00 |
| Headache |
OR 0.65, 95% CI 0.17 to 2.40; 1 study, 142 participants |
P = 0.51 |
| Muscle weakness |
OR 2.29, 95% CI 0.91 to 5.76; 1 study, 142 participants |
P = 0.08 |
| Nausea |
OR 0.40, 95% CI 0.17 to 0.95; 1 study, 142 participants |
P = 0.04 |
| Paraesthesia |
OR 1.43, 95% CI 0.68 to 2.99; 1 study, 142 participants |
P = 0.35 |
| Speech‐related problems |
OR 1.00, 95% CI 0.24 to 4.16; 1 study, 142 participants |
P = 1.00 |
| Tremor |
OR 1.60, 95% CI 0.73 to 3.48; 1 study, 142 participants |
P = 0.24 |
